<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-671X</journal-id>
<journal-title><![CDATA[Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Medicina Interna]]></abbrev-journal-title>
<issn>0872-671X</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-671X2024000100002</article-id>
<article-id pub-id-type="doi">10.24950/rspmi.2176</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Are COMPASS Candidates Among Internal Medicine Patients? Insights from the Internal Medicine Clinic]]></article-title>
<article-title xml:lang="pt"><![CDATA[Serão os Doentes da Medicina Interna Candidatos à Estratégia COMPASS? Perceções da Consulta de Medicina Interna]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Julião]]></surname>
<given-names><![CDATA[Sofia Rosado]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Andreia Rodrigues]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palácios]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sargento]]></surname>
<given-names><![CDATA[Dora Lemos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidade Local de Saúde de Santa Maria Serviço de Saúde Ocupacional ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Unidade Local de Saúde de Santa Maria Serviço de Medicina Interna ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Clínica Unidade Local de Saúde de Santa Maria Unidade de Farmacologia ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidade de Lisboa Faculdade de Medicina Laboratório de Farmacologia Clínica e Terapêutica]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidade de Lisboa Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Unidade Local de Saúde Santa Maria Unidade de Ortogeriatria ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>2</fpage>
<lpage>9</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-671X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-671X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-671X2024000100002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  We sought to evaluate if internal medicine outpatients are candidates to COMPASS trial strategy (low dose rivaroxaban twice a day plus daily acetylsalicylic acid), to detail the inclusion and exclusion criteria of COMPASS trial presented by internal medicine patients and to evaluate the frequency of patients already under the strategy.  Methods:  Observational, retrospective, and transversal study in an internal medicine department of a tertiary university hospital. During a one-month period, we consulted all electronic medical records of internal medicine appointments to assess which patients presented inclusion and exclusion criteria of the COMPASS trial.  Results:  Of 228 patients, 40 (17.5%) met inclusion criteria for COMPASS trial. Twelve (30.0%) had coronary artery disease, 21 (52.5%) had peripheral artery disease, and 6 (1.5%) had both. One patient was already on the COMPASS trial strategy. Of those who met inclusion criteria, 70.0% (n = 28) presented at least one exclusion criteria. The most frequent was the use of oral anticoagulation (mostly due to atrial fibrillation), followed by the users of non-acetylsalicylic acid antiplatelet therapy.  Conclusion:  The number of internal medicine patients who are eligible to benefit from the COMPASS strategy is relevant. Internal medicine physicians must be aware of inclusion and exclusion criteria of this new prevention strategy to promptly apply it in clinical practice.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  O nosso objetivo foi avaliar se os doentes seguidos em consulta de Medicina Interna são elegíveis para a estratégia do estudo COMPASS (dose baixa de rivaroxabano bidiária e ácido acetilsalicílico diário), detalhar os seus critérios de inclusão e de exclusão e definir a frequência de doentes que já se encontravam sob esta estratégia terapêutica.  Métodos:  Estudo observacional, retrospetivo e transversal realizado num departamento de medicina interna de um hospital universitário e terciário. Durante um período de um mês, consultámos todos os registos médicos eletrónicos das consultas de Medicina Interna para avaliar quais os doentes que apresentavam critérios de inclusão e exclusão do estudo COMPASS.  Resultados:  Dos 228 doentes, 40 (17,5%) preenchiam os critérios de inclusão do estudo COMPASS. Doze (30,0%) tinham doença arterial coronária, 21 (52,5%) tinham doença arterial periférica e 6 (1,5%) tinham ambas. Um doente já se encontrava sob a estratégia. Dos que preenchiam os critérios de inclusão, 70,0% (n = 28) apresentavam, pelo menos, um critério de exclusão. O mais frequente era a anticoagulação oral (principalmente para o tratamento da fibrilhação atrial), seguido pela terapêutica antiplaquetária sem ácido acetilsalicílico.  Conclusão:  O número de doentes seguido em consulta de Medicina Interna elegíveis para beneficiar da estraté-gia do estudo COMPASS é relevante. Os internistas devem estar despertos para os critérios de inclusão e exclusão desta nova estratégia de prevenção para aplicá-la prontamente na prática clínica.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Aspirina/uso terapêutico]]></kwd>
<kwd lng="pt"><![CDATA[Doença Artéria Coronária/tratamento farmacológico]]></kwd>
<kwd lng="pt"><![CDATA[Doença Arterial Periférica/tratamento farmacológico]]></kwd>
<kwd lng="pt"><![CDATA[Rivaroxabana/uso terapêutico.]]></kwd>
<kwd lng="en"><![CDATA[Aspirin/therapeutic use]]></kwd>
<kwd lng="en"><![CDATA[Coronary Artery Disease/drug therapy]]></kwd>
<kwd lng="en"><![CDATA[Peripheral Arterial Disease/drug therapy]]></kwd>
<kwd lng="en"><![CDATA[Rivaroxaban/therapeutic use.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dagenais]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Shestakovska]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<page-range>1319-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steffel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Shestakovska]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KAA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The COMPASS Trial net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>142</volume>
<page-range>40-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walley]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic conservatism]]></article-title>
<source><![CDATA[J R Coll Physicians Lond]]></source>
<year>1993</year>
<volume>27</volume>
<page-range>198-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lapostolle]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Petrovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Goix]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Adnet]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of COVID-19 pandemic on non-COVID-19 publications]]></article-title>
<source><![CDATA[Resuscitation]]></source>
<year>2021</year>
<volume>162</volume>
<page-range>102-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bahat]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Boureau]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ozkok]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pfister]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pilotto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation a geriatric perspective on the 2020 ESC guidelines]]></article-title>
<source><![CDATA[Eur Geriatr Med]]></source>
<year>2022</year>
<volume>13</volume>
<page-range>5-18</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Elbez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[External applicability of the COMPASS trial an analysis of the reduction of atherothrombosis for continued health (REACH) registry]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2018</year>
<volume>39</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>750-7a</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Luca]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Formigli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meessen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Uguccioni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Paolillo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases insights from the START registry]]></article-title>
<source><![CDATA[Eur Heart J Qual Care Clin Outcomes]]></source>
<year>2021</year>
<volume>7</volume>
<page-range>513-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lapébie]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lacroix]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Constans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boulon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Messas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France The COPART Registry]]></article-title>
<source><![CDATA[Eur J Vasc Endovasc Surg]]></source>
<year>2021</year>
<volume>62</volume>
<page-range>439-49</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faria]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baptista]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome]]></article-title>
<source><![CDATA[Rev Port Cardiol]]></source>
<year>2020</year>
<volume>39</volume>
<page-range>493-501</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
